
    
      This single-center, randomized, double-blind, placebo-controlled, parallel-group trial will
      evaluate pain and quality of life outcomes associated with 6 months of treatment with
      testosterone or placebo in men aged 18 years or older with chronic non-cancer back pain who
      are taking opioid analgesics for at least 6 months and have opioid-induced hypogonadism.
    
  